Nurix Therapeutics (NRIX) Cash from Financing Activities (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Cash from Financing Activities data on file, last reported at $66000.0 in Q2 2026.

• On a quarterly basis, Cash from Financing Activities rose 1000.0% year-over-year to $66000.0 in Q2 2026; TTM through May 2026 was $257.2 million, a 3.81% increase from a year earlier, with the FY2025 full-year figure at $238.6 million, down 50.86% from the prior year.
• Cash from Financing Activities for Q2 2026 stood at $66000.0, down from $20.0 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for NRIX reached as high as $237.8 million in Q2 2024 and fell as low as -$135000.0 in Q4 2022.
• Historically, Cash from Financing Activities has averaged $48.0 million across 5 years, with a median of $1.5 million in 2022.
• Across the five-year window, Cash from Financing Activities sank 127.0% in 2022 and surged 2864485.71% in 2024, its largest moves.
• Year by year, Cash from Financing Activities stood at -$135000.0 in 2022, then jumped by 105.19% to $7000.0 in 2023, then jumped by 2864485.71% to $200.5 million in 2024, then grew by 17.7% to $236.0 million in 2025, then sank by 99.97% to $66000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $66000.0 in Q2 2026, $20.0 million in Q1 2026, and $236.0 million in Q4 2025.